ESR1 and cancer: In 2004, series of triorganophosphinegold(i) dithiocarbamate (R3PAuS2CNR2) compounds were synthesized and their cytotoxicity evaluated against seven human cancer cell lines namely: A498, renal cancer; MCF-7, estrogen receptor (ER)+/progesterone receptor (PgR)+; EVSA-T, estrogen receptor (ER)/progesterone receptor (PgR)−; H226, non-small cell lung cancer; GROV, ovarian cancer; Ml9 MEL, melanoma; and WIDR, colon cancer.